{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myasthenia+Gravis%2C+Generalized", "query": { "condition": "Myasthenia Gravis, Generalized" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 83, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myasthenia+Gravis%2C+Generalized&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T01:40:43.590Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06106672", "title": "Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myasthenia Gravis", "Generalized Myasthenia", "AChR Myasthenia Gravis", "MuSK MG" ], "interventions": [ { "name": "CNP-106", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "COUR Pharmaceutical Development Company, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 54, "start_date": "2024-05-30", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Brea, California • Orange, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Brea", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06106672" }, { "nct_id": "NCT06799247", "title": "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthaenia Gravis" ], "interventions": [ { "name": "Decartes-08", "type": "BIOLOGICAL" }, { "name": "Placebo Drug", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Cartesian Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-05-06", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 23, "location_summary": "Tucson, Arizona • Carlsbad, California • Los Angeles, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799247" }, { "nct_id": "NCT07217587", "title": "Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthenia Gravis" ], "interventions": [ { "name": "Nipocalimab", "type": "DRUG" }, { "name": "Efgartigimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 115, "start_date": "2026-01-05", "completion_date": "2028-12-11", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 9, "location_summary": "Pomona, California • Fort Collins, Colorado • Farmington, Connecticut + 6 more", "locations": [ { "city": "Pomona", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "O'Fallon", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217587" }, { "nct_id": "NCT04115293", "title": "Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthenia Gravis, Generalized" ], "interventions": [ { "name": "zilucoplan (RA101495)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ra Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 174, "start_date": "2019-09-17", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 37, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115293" }, { "nct_id": "NCT07039916", "title": "Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "IMVT-1402", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 231, "start_date": "2025-05-27", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 45, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 40 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07039916" }, { "nct_id": "NCT02473965", "title": "Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myasthenia Gravis" ], "interventions": [ { "name": "IGIV-C", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 60, "start_date": "2015-06", "completion_date": "2019-02", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 14, "location_summary": "Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02473965" }, { "nct_id": "NCT03304054", "title": "Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthenia Gravis, Generalized" ], "interventions": [ { "name": "Amifampridine Phosphate", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Catalyst Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2018-04-18", "completion_date": "2020-03-15", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03304054" }, { "nct_id": "NCT03772587", "title": "A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "M281", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Momenta Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2019-04-10", "completion_date": "2020-06-25", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03772587" }, { "nct_id": "NCT05514873", "title": "An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "zilucoplan (RA101495)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 26, "start_date": "2022-10-31", "completion_date": "2024-10-23", "has_results": true, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "O'Fallon", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05514873" }, { "nct_id": "NCT07596901", "title": "Study of Aritinercept in Patients With Generalized Myasthenia Gravis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myasthenia Gravis, Generalized" ], "interventions": [ { "name": "Aritinercept", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Aurinia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 81, "start_date": "2026-04-22", "completion_date": "2029-03-02", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T01:40:43.590Z", "location_count": 3, "location_summary": "Altamonte Springs, Florida • Boca Raton, Florida • Miami, Florida", "locations": [ { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07596901" } ] }